BLBrian Loughery

Brian Loughery

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brian Loughery has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Photodynamic Therapy as a Potent Radiosensitizer in Head and Neck Squamous Cell Carcinoma

    by Won Jin Cho, David Kessel, Joseph Rakowski, Brian Loughery, Abdo J. Najy, Tri Pham, Seongho Kim, Yong Tae Kwon, Ikuko Kato, Harold E. Kim, et al.

    Despite recent advances in therapeutic modalities such as radiochemotherapy, the long-term prognosis for patients with advanced head and neck squamous cell carcinoma (HNSCC), especially nonviral HNSCC, remains very poor, while survival of patients with human papillomavirus (HPV)-associated HNSCC is greatly improved after radiotherapy. The goal of this study is to develop a mechanism-based treatment protocol for high-risk patients with HPV-negative HNSCC. To achieve our goal, we have investigated molecular mechanisms underlying differential radiation sensitivity between HPV-positive and -negative HNSCC cells. Here, we found that autophagy is associated with radioresistance in HPV-negative HNSCC, whereas apoptosis is associated with radiation sensitive HPV-positive HNSCC. Interestingly, we found that photodynamic therapy (PDT) directed at the endoplasmic reticulum (ER)/mitochondria initially induces paraptosis followed by apoptosis. This led to a substantial increase in radiation responsiveness in HPV-negative HNSCC, while the same PDT treatment had a minimal effect on HPV-positive cells. Here, we provide evidence that the autophagic adaptor p62 mediates signal relay for the induction of apoptosis, promoting ionizing radiation (XRT)-induced cell death in HPV-negative HNSCC. This work proposes that ER/mitochondria-targeted PDT can serve as a radiosensitizer in intrinsically radioresistant HNSCC that exhibits an increased autophagic flux.


  • A proof of concept kilovoltage intensity modulated radiotherapy platform for the treatment of glioblastoma multiforme

    by Brian Loughery, Robert Halford, Kathryn Dess, Joseph Rakowski, Mary Cox, Joseph Koh, Alan Mayville, Jeffery Riess, Michael Snyder

    Purpose : To develop a compact, proof-of-concept kilovoltage intensity modulated radiotherapy platform to deliver contrast-enhanced radiotherapy (CERT). Methods : The proof-of-concept requirements were threefold: (i) develop a compact means to generate a kilovoltage x-ray broadbeam capable of targeting the K-edge of heavy metal contrast, (ii) investigate the potential clinical application of such a beam in silico , and (iii) construct a limited working prototype of the platform to identify weaknesses in the approach. The x-ray broadbeam was created with a standard kilovoltage x-ray tube heavily filtered with 0.156 mm tungsten. Depth dose and treatment characteristics of the beam were investigated using GEANT4 Monte Carlo framework. The working prototype included a miniaturized multi-rod collimator (MRC) constructed with tungsten carbide rods, 3D-printed gear rack, and an in-house GUI/microprocessor assembly. Measurements of simulated treatments were made with EBT3 radiochromic film. Results : Monte Carlo simulations of pseudo-clinical treatments on a homogeneous spherical Lucite phantom produced dose distributions that indicated surface dose was less than target dose. When simulated-bone was added to the calculations, dose-to-bone was found to be the probable limiting factor in clinical treatment. Nevertheless, when iodine contrast enhancement was accounted for, dose was escalated in the tumor compared to standard megavoltage treatments even with dose-to-bone limitations. Experimentally, after commissioning the MRC and calibrating the radiochromic film, surface dose was compared to maximum dose measured on each film. Surface dose measurements were higher than those in a megavoltage beam, but below the skin toxicity threshold. Dose at depth was reasonable despite increased beam attenuation at these energies from photoelectric interactions in bone. IMRT and non-coplanar dose falloffs around the target were steeper than kV 3D conformal dose falloff. Conclusions : The compact kilovoltage treatment platform presented here proved clinically feasible in both simulation and measurement. It is reasonable to pursue this modality further as a potential CERT platform.


  • Multi-institutional evaluation of end-to-end protocol for IMRT/VMAT treatment chains utilizing conventional linacs

    by Brian Loughery, Cory Knill, Evan Silverstein, Viatcheslav Zakjevskii, Kathryn Masi, Elizabeth Covington, Karen Snyder, Kwang Song, Michael Snyder


  • Open Access

    Commissioning of a dedicated commercial Co‐60 total body irradiation unit

    by Jay Burmeister, Adrian Nalichowski, Michael Snyder, Robert Halford, Geoff Baran, Brian Loughery, Ahmad Hammoud, Joe Rakowski, Todd Bossenberger

    We describe the commissioning of the first dedicated commercial total body irradiation (TBI) unit in clinical operation. The Best Theratronics GammaBeam 500 is a Co‐60 teletherapy unit with extended field size and imaging capabilities. Radiation safety, mechanical and imaging systems, and radiation output are characterized. Beam data collection, calibration, and external dosimetric validation are described. All radiation safety and mechanical tests satisfied relevant requirements and measured dose distributions meet recommendations of American Association of Physicists in Medicine (AAPM) Report #17. At a typical treatment distance, the dose rate in free space per unit source activity using the thick flattening filter is 1.53 × 10−3 cGy*min−1*Ci−1. With a 14,000 Ci source, the resulting dose rate at the midplane of a typical patient is approximately 17 and 30 cGy/min using the thick and thin flattening filters, respectively, using the maximum source to couch distance. The maximum useful field size, defined by the 90% isodose line, at this location is 225 × 78 cm with field flatness within 5% over the central 178 × 73 cm. Measured output agreed with external validation within 0.5%. End‐to‐end testing was performed in a modified Rando phantom. In‐house MATLAB software was developed to calculate patient‐specific dose distributions using DOSXYZnrc, and fabricate custom 3D‐printed forms for creating patient‐specific lung blocks. End‐to‐end OSLD and diode measurements both with and without lung blocks agreed with Monte Carlo calculated doses to within 5% and in‐phantom film measurements validated dose distribution uniformity. Custom lung block transmission measurements agree well with design criteria and provide clinically favorable dose distributions within the lungs. Block placement is easily facilitated using the flat panel imaging system with an exposure time of 0.01 min. In conclusion, a novel dedicated TBI unit has been commissioned and clinically implemented. Its mechanical, dosimetric, and imaging capabilities are suitable to provide state‐of‐the‐art TBI for patients as large as 220 cm in height and 78 cm in width.


  • Open Access

    Navigating the medical physics education and training landscape

    by Brian Loughery, George Starkschall, Kristi Hendrickson, Joann Prisciandaro, Brenda Clark, Gary Fullerton, Geoffrey Ibbott, Edward Jackson, Jay Burmeister

    Purpose: The education and training landscape has been profoundly reshaped by the ABR 2012/2014 initiative and the MedPhys Match. This work quantifies these changes and summarizes available reports, surveys, and statistics on education and training.Methods: We evaluate data from CAMPEP‐accredited program websites, annual CAMPEP graduate and residency program reports, and surveys on the MedPhys Match and Professional Doctorate degree (DMP).Results: From 2009–2015, the number of graduates from CAMPEP‐accredited graduate programs rose from 210 to 332, while CAMPEP‐accredited residency positions rose from 60 to 134. We estimate that approximately 60% of graduates of CAMPEP‐accredited graduate programs intend to enter clinical practice, however, only 36% of graduates were successful in acquiring a residency position in 2015. The maximum residency placement percentage for a graduate program is 70%, while the median for all programs is only 22%. Overall residency placement percentage for CAMPEP‐accredited program graduates from 2011–2015 was approximately 38% and 25% for those with a PhD and MS, respectively. The disparity between the number of clinically oriented graduates and available residency positions is perceived as a significant problem by over 70% of MedPhys Match participants responding to a post‐match survey. Approximately 32% of these respondents indicated that prior knowledge of this situation would have changed their decision to pursue graduate education in medical physics.Conclusion: These data reveal a substantial disparity between the number of residency training positions and graduate students interested in these positions, and a substantial variability in residency placement percentage across graduate programs. Comprehensive data regarding current and projected supply and demand within the medical physics workforce are needed for perspective on these numbers. While the long‐term effects of changes in the education and training infrastructure are still unclear, available survey data suggest that these changes could negatively affect potential entrants to the profession.